4//SEC Filing
Vardzel Gerald J Jr 4
Accession 0001179110-20-004703
CIK 0001446159other
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 4:36 PM ET
Size
9.9 KB
Accession
0001179110-20-004703
Insider Transaction Report
Form 4
Vardzel Gerald J Jr
Director
Transactions
- Conversion
Common Stock, $.01 par value
2019-04-04+62,843→ 154,415 total - Award
Stock Options (right to buy)
2020-03-31+3,174→ 3,174 totalExercise: $1.58From: 2020-03-31Exp: 2030-03-31→ Commmon Stock (3,174 underlying) - Conversion
Series D Convertible Preferred Stock
2020-04-04−62,843→ 0 totalFrom: 2020-04-04Exp: 2020-04-04→ Common Stock (62,843 underlying)
Footnotes (3)
- [F1]The reporting person acquired 71,821 shares (on a post split basis) of issuer common stock in exchange for an 18% interest in Helomics Holding Corporation ("Helomics") pursuant to Helomics merger into the issuer. Of the 71,821 shares issued to the reporting person in the merger, 17,542 are currently being held in escrow and are subject to forfeiture during the escrow period (until 9/30/2020), to satisfy any claims arising as a result of any breach by Helomics of any of its representations and warranties or covenants in the merger agreement.
- [F2]Share ownership numbers have been adjusted to take into account the 1-for-10 reverse stock split which occurred on October 25, 2019.
- [F3]Series D Convertible Preferred Stock converted automatically to Common Stock on April 4, 2020 for no additional consideration.
Documents
Issuer
Predictive Oncology Inc.
CIK 0001446159
Entity typeother
Related Parties
1- filerCIK 0001751315
Filing Metadata
- Form type
- 4
- Filed
- Apr 5, 8:00 PM ET
- Accepted
- Apr 6, 4:36 PM ET
- Size
- 9.9 KB